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A bs tr ac t
Background
Artemisinin resistance in Plasmodium falciparum has emerged in Southeast Asia and now 
poses a threat to the control and elimination of malaria. Mapping the geographic ex-
tent of resistance is essential for planning containment and elimination strategies.
Methods
Between May 2011 and April 2013, we enrolled 1241 adults and children with acute, 
uncomplicated falciparum malaria in an open-label trial at 15 sites in 10 countries 
(7 in Asia and 3 in Africa). Patients received artesunate, administered orally at a 
daily dose of either 2 mg per kilogram of body weight per day or 4 mg per kilogram, 
for 3 days, followed by a standard 3-day course of artemisinin-based combination 
therapy. Parasite counts in peripheral-blood samples were measured every 6 hours, 
and the parasite clearance half-lives were determined.
Results
The median parasite clearance half-lives ranged from 1.9 hours in the Democratic 
Republic of Congo to 7.0 hours at the Thailand–Cambodia border. Slowly clearing 
in fections (parasite clearance half-life >5 hours), strongly associated with single point 
mutations in the “propeller” region of the P. falciparum kelch protein gene on chromo-
some 13 (kelch13), were detected throughout mainland Southeast Asia from southern 
Vietnam to central Myanmar. The incidence of pretreatment and post-treatment ga-
metocytemia was higher among patients with slow parasite clearance, suggesting 
greater potential for transmission. In western Cambodia, where artemisinin-based 
combination therapies are failing, the 6-day course of antimalarial therapy was as-
sociated with a cure rate of 97.7% (95% confidence interval, 90.9 to 99.4) at 42 days.
Conclusions
Artemisinin resistance to P. falciparum, which is now prevalent across mainland 
Southeast Asia, is associated with mutations in kelch13. Prolonged courses of arte-
misinin-based combination therapies are currently efficacious in areas where stan-
dard 3-day treatments are failing. (Funded by the U.K. Department of International 
Development and others; ClinicalTrials.gov number, NCT01350856.)
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A rtemisinin derivatives are highly potent, rapidly eliminated antimalarial drugs with a broad stage specificity of 
action. They clear parasitemia more rapidly than 
all other currently available antimalarial agents. 
In the 1990s, resistance to available antimalar-
ial drugs such as chloroquine and sulfadoxine–
pyrimethamine worsened across areas of the 
world where malaria is endemic. As a direct con-
sequence, morbidity and mortality associated 
with malaria increased, especially among African 
children, who account for most deaths from ma-
laria.1 The artemisinin-based combination thera-
pies were introduced in the mid-1990s, when 
there was an imminent prospect of untreatable 
malaria in Southeast Asia, where resistance to all 
available antimalarial drugs had developed. In 
2005, the World Health Organization (WHO) rec-
ommended that artemisinin-based com bination 
therapies be used as first-line treatments for falci-
parum malaria in all countries where malaria 
was endemic. Recent, marked increases in the 
availability and use of artemisinin-based combi-
nation therapies, together with the increased use 
of insecticide-treated bed nets, have substantially 
reduced global morbidity and mortality from 
malaria.2 These gains, and the prospects for the 
elimination of malaria, are now threatened by 
the emergence of artemisinin resistance in Plas­
modium falciparum. Artemisinin resistance is char-
acterized by slow parasite clearance,3,4 which re-
flects the reduced susceptibility of ring-stage 
parasites.5-9 It has recently been linked with point 
mutations in the “propeller” region of a P. falci­
parum kelch protein.10
Artemisinin resistance was reported first 
in western Cambodia,3,4 where failure rates for 
artemisinin-based combination therapies are rap-
idly increasing11 and where resistance to pre-
vious first-line antimalarial drugs also first 
emerged. Artemisinin resistance has since spread, 
emerged independently, or both in other areas of 
mainland Southeast Asia.12-15 On the Thailand–
Myanmar border, the geometric mean half-life 
for parasite clearance increased from 2.6 hours 
in 2001 to 3.7 hours in 2010, as compared with 
a half-life of 5.5 hours in western Cambodia 
between 2007 and 2010.12 Defining the extent 
and severity of artemisinin resistance is essen-
tial for planning containment and elimination 
strategies.
The Tracking Resistance to Artemisinin Col-
laboration was created in 2011 to provide evi-
dence and tools to halt or slow the spread of 
artemisinin resistance. The principal objective of 
our clinical research was to map the current 
extent and severity of artemisinin resistance.
Me thods
Study Design and Oversight
We conducted an open-label, randomized trial 
at 15 sites in 10 countries (Fig. 1): Cambodia 
(4 sites), Thailand (3 sites), and Laos, Vietnam, 
Myanmar, Bangladesh, India, Nigeria, Kenya, 
and the Democratic Republic of Congo (1 site each). 
The study was coordinated by the Mahidol– 
Oxford Tropical Medicine Research Unit (MORU) 
in Bangkok.
The protocol (available with the full text of 
this article at NEJM.org) was approved by the 
Oxford Tropical Research Ethics Committee and 
the institutional review board, national ethics 
committee, or both for each site. The trial was 
monitored by the MORU Clinical Trials Support 
Group, in collaboration with the Oxford Univer-
sity Clinical Research Unit–Vietnam and the 
Kenya Medical Research Institute–Wellcome Trust 
Clinical Trials Facility. All serious adverse events 
were reported to an independent data and safety 
monitoring committee. Quality-assured artesunate 
manufactured  by Guilin Pharmaceutical was pro-
vided by the WHO Global Malaria Programme, 
and artemisinin-based combination therapies 
were provided free of charge by Beijing Holley-
Cotec Pharmaceuticals and Sigma-Tau Pharma-
ceuticals; these companies did not play a role in 
the study design, data collection or analysis, or 
writing of the manuscript.
Study Sites and Patients
Patients were eligible for enrollment in the study 
if they were 6 months to 65 years of age and had 
acute, uncomplicated falciparum malaria (in-
cluding mixed infections with non-falciparum 
species), parasitemia with a parasite count be-
Figure 1 (facing page). Location of Study Sites and 
 Proportions of Patients with Artemisinin Resistance.
Artemisinin resistance was defined by a parasite clear-
ance half-life longer than 5 hours, with some Plasmodium 
falciparum isolates having kelch13 polymorphisms (at or 
beyond amino acid position 441).
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tween 10,000 and 200,000 per cubic millimeter, 
and fever (a tympanic temperature >37.5°C) or a 
history of fever. Patients or parents or guardians 
of minors who were unable to read or write pro-
vided oral informed consent in the presence of an 
impartial witness. Assent was obtained from mi-
nors older than 10 years of age. All other patients 
provided written informed consent. The main 
exclusion criteria were receipt of an artemisinin 
antimalarial drug in the previous week, pregnancy 
or breast-feeding, and a low hematocrit (<25% in 
Asia and <15% in Africa).
Drug Therapy and Follow-up Assessments
At most sites, patients were randomly assigned in 
blocks of 20 to receive artesunate (Guilin Pharma-
ceutical), administered orally at a dose of either 
2 mg per kilogram of body weight per day or 4 mg 
per kilogram per day, for 3 days, followed by a stan-
dard 3-day course of an artemisinin-based combi-
nation therapy (dihydroartemisinin–piperaquine, 
artemether–lumefantrine, artesunate–sulfadoxine–
pyrimethamine, or artesunate–mefloquine, accord-
ing to local treatment policies). Treatment as-
signments were concealed in numbered opaque 
envelopes, which were opened sequentially. In 
western Cambodia, and Srisaket, Thailand, where 
higher-grade artemisinin resistance was already 
established, only the higher dose of artesunate 
(4 mg per kilogram per day) was evaluated. In 
response to review by local scientific or ethics 
committees, the protocol was modified as follows: 
in India, only the higher dose of artesunate was 
studied, patients in the Democratic Republic of 
Congo received either artemether–lumefantrine 
alone or artesunate at a dose of 4 mg per kilo-
gram per day for 3 days, followed by artemether–
lumefantrine, and in Kenya, artesunate was ad-
ministered at a daily dose of 2 mg per kilogram 
per day for 7 days.
Patients were admitted to the hospital for 
supervised treatment. Body temperature and 
hematocrit were measured and blood smears for 
parasite counts were obtained at 0, 4, 6, 8, and 
12 hours and then every 6 hours thereafter until 
two consecutive slides were reported as negative.
Follow-up assessments were performed on 
days 7 and 14 at all study sites; patients were 
followed weekly for 28 or 42 days at six sites. For 
recurrent infections, polymerase-chain-reaction 
(PCR) genotyping was performed with the use of 
msp1, msp2, and glurp as genetic markers to dis-
tinguish a recrudescence from a newly acquired 
infection.16 In Kenya, only msp2 was used for 
genotyping.17
Genetic Markers of Artemisinin Resistance
After PCR amplification, the full sequence of 
kelch13 was determined from P. falciparum isolates 
obtained at admission (see the Supplementary 
Appendix, available at NEJM.org).10
microscopy quality-control measures
Quality control of microscopy throughout the 
study was performed by experienced microsco-
pists at four of the study sites. All slides obtained 
at admission and at 72 hours were rechecked. 
Complete patient slide sets were rechecked if the 
standard deviation of residuals for the fit to the 
linear segment of the parasite–time profile (see 
below) was greater than 1, the estimated lag 
phase was longer than 12 hours, the clearance 
estimate was based on two positive counts, or 
the last positive parasite count was greater than 
1000 per cubic millimeter.
Study Outcomes
The primary outcome was the parasite clear-
ance half-life, a measure of the parasite clearance 
rate derived from the linear segment of the 
log parasitemia–time curve (parasite clearance 
half-life = loge2 divided by the parasite clearance 
rate).18-20 Secondary outcomes were the propor-
tions of patients with a parasite clearance half-
life of more than 5 hours, parasitemia detected 
on microscopy21 on day 3, gametocytemia after 
treatment, the incidence of anemia, and the ef-
ficacy of the 6-day artesunate regimen plus ar-
temisinin-based combination therapy, corrected 
by means of PCR genotyping.17
Statistical Analysis
Sample-size calculations were based on parasite 
clearance rates among 1952 patients treated with 
oral artesunate between 2001 and 2010 in north-
west Thailand,12 which had a log-normal distri-
bution, with geometric mean clearance rates be-
tween 0.19 and 0.24 per hour and log-scale 
standard deviations between 0.40 and 0.55 (coef-
ficient of variation on the original scale, 43 to 
49%). On the basis of the log-linear component 
of the parasitemia–time slope, we calculated that 
a sample of 50 patients per group at each site 
would provide 12, 15, and 17% precision and 
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80% power to detect a 20%, 25%, and 27% de-
crease in the geometric mean of parasite clear-
ance rates for rates between 0.17 and 0.30 per 
hour, assuming log-transformed standard-devia-
tion values of 0.40, 0.50, and 0.55, respectively. 
We calculated that we would need to enroll 60 
patients per group to allow for a 10% loss to 
follow-up or incomplete data.
Data were double-entered into a Web-based 
database (OpenClinica, version 3.0) and cleaned 
and analyzed with the use of Stata software, ver-
sion 13 (StataCorp). Parasite clearance was assessed 
with the use of the WorldWide Antimalarial Re-
sistance Network Parasite Clearance Estimator.19,20 
Half-life values were excluded from numerical 
comparisons in 14 patients, since these values 
were based on only two data points. The rela-
tionships between kelch13 mutations and para-
site clearance measures were assessed by means 
of multivariable analysis. A parasite clearance 
half-life longer than 5.0 hours was considered 
prospectively to indicate artemisinin resistance on 
the basis of data from the Thailand–Myanmar 
border (where this was the 90th centile for para-
site clearance half-life in 2004, when resistance 
had just emerged).12 Resolution of fever and treat-
ment efficacy corrected by means of PCR geno-
typing were estimated with the use of Kaplan–
Meier survival analysis.22,23 A meta-analysis of 
the differences in mean log-transformed para-
site clearance half-life values between treatment 
groups was performed according to study site 
with the use of the inverse-variance method and 
a fixed-effects model. Heterogeneity was evalu-
ated with the use of the I2 statistic.24 All com-
parisons were stratified according to study site 
with the use of random-effects or fixed-effects 
models. Anemia was defined as a hemoglobin 
level below 11 g per deciliter (<10 g per deciliter 
in children younger than 5 years of age). Full 
details of the study conduct and analyses are 
provided in the protocol with the statistical 
analysis plan.
R esult s
Study Patients
Between May 2011 and April 2013, a total of 
18,865 patients were screened and 1241 patients 
with falciparum malaria were enrolled, of whom 
829 (67%) were febrile on admission. The coinci-
dent strengthening of efforts to control malaria 
and the decreasing incidence of malaria prevented 
7 of the 15 sites from meeting recruitment tar-
gets. The majority of patients were men (74%). 
The median age was 21 years (interquartile range, 
11 to 31) (Table 1).
Parasite Clearance
There were marked differences in therapeutic re-
sponses across the Southeast Asian sites. Median 
parasite clearance half-life values ranged from 
2 hours in Attapeu, Laos, to 7 hours in Srisaket, 
Thailand (approximately 250 km [155 mi] to the 
west) (Table 2). There was a gradient of pro-
longed parasite clearance, with the highest pro-
portion of patients with a prolonged parasite 
clearance half-life (>5 hours) in western Cambo-
dia and eastern Thailand (49 to 73%), as com-
pared with 14 to 28% in northern Cambodia, 
Vietnam, and eastern Myanmar, and very low 
proportions elsewhere. (Fig. 1 and 2 and Table 2). 
The proportions of patients with parasitemia 
 detectable on microscopy at 72 hours (day 3), 
a widely used criterion for artemisinin resis-
tance,21 ranged from 0% in Kenya to 68% in east-
ern Thailand (Table 2). Among the African sites, 
median parasite clearance half-life values were 
similar in Kenya and Nigeria (P = 0.75) but were 
significantly shorter in the Democratic Republic 
of Congo than in these two African sites (P<0.001) 
(Fig. 2 and Table 2).
Geometric mean parasite clearance half-life 
values were similar in the group that received 
artesunate at a dose of 2 mg per kilogram and 
the group that received artesunate at a dose of 
4 mg per kilogram; the overall difference, 
stratified according to site, was −4.9% (95% 
confidence interval [CI], −10.7 to 1.4; P = 0.13). 
In Kin shasa, median parasite clearance half-life 
values were significantly longer with artemether– 
lumefantrine than with artesunate at a dose of 
4 mg per kilogram (2.2 hours [range, 1.2 to 4.6] 
vs. 1.9 hours [range, 0.7 to 7.0]; P = 0.003).
Genetic Correlates of Slow Parasite Clearance
Single point mutations in the propeller domain 
of kelch13 after position 440 were associated with 
a mean increase in the parasite clearance half-life 
of 116% (95% CI, 103 to 131; P<0.001) (Fig. 2). In 
a multivariate logistic-regression model, with ad-
justment for age, baseline parasite count, and 
dose of artesunate, an infection associated with 
a kelch13 propeller mutation was substantially 
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more likely to have a parasite clearance half-life 
longer than 5 hours (odds ratio, 94.7; 95% CI, 
54.6 to 164.0; P<0.001). In this study, kelch13 pro-
peller mutations had 91.8% sensitivity and 88.4% 
specificity in identifying a parasite clearance 
half-life longer than 5 hours. Among infections 
with wild-type kelch13 alleles, 3.4% (21 of 611) had 
a parasite clearance half-life longer than 5 hours. 
The parasite clearance half-life values for mutant 
infections were generally similar, except that the 
values associated with G538V were lower and 
those associated with I543T and N458Y were 
higher than the half-life values associated with 
the other mutations (P = 0.02).
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Figure 2. Distribution of Parasite Clearance Half-Lives
.
Panel A shows the parasite clearance half-life according to study site (treatment groups have been pooled in all sites), and Panel B shows 
the location of P. falciparum kelch13 nonsynonymous polymorphisms. One circle represents one patient. Infections with mutations in 
the P. falciparum kelch13 are indicated by blue circles (wild-type or mutation before amino acid position 441), red circles (mutation after 
position 440), or black circles (at least part of kelch13 sequence is missing or heterozygous). Two patients had double mutations (n87k 
and k92n, and p441l and n725y); the site of the first mutation is shown.
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Gametocyte Carriage
Patent gametocytemia (gametocyte densities above 
the microscopy level of detection) was reported 
in 125 patients at enrollment, with the highest 
rates in the Democratic Republic of Congo (31%) 
and western Cambodia (19% in Pailin and 18% in 
Pursat). The median duration of patent gametocy-
temia was 6.7 days (range, <6 hours to 10.5 days); 
it did not differ significantly between the sites 
(P = 0.36) and was not correlated with the parasite 
clearance half-life. Gametocytemia developed in 
an additional 48 patients within 24 hours and in 
another 47 patients between day 1 and day 7 (me-
dian time to appearance, 42 hours; range, 24 to 
169). The prevalence of gametocytemia at enroll-
ment was higher among patients at sites with 
slow parasite clearance. Excluding the Democrat-
ic Republic of Congo, which has substantially 
higher malaria transmission intensity than the 
other sites, patent gametocytemia was also more 
likely to develop in patients with slower parasite 
clearance after treatment (odds ratio for doubling 
of the parasite clearance half-life, 2.40; 95% CI, 
1.53 to 3.76; P<0.001).
Hematologic findings
More than half the African children enrolled in the 
study had anemia, as compared with 8 to 37% of 
Asian patients. The lowest hematocrit occurred on 
day 3, with partial recovery by day 14. Four patients 
(one child in the Democratic Republic of Congo 
and three adults in Thailand) received a blood 
transfusion during the first week. After adjustment 
for the baseline hematocrit, baseline parasite 
count, age, and the total dose of the artemisinin 
derivative received, delayed recovery from anemia 
on day 21 was associated with slow parasite clear-
ance (odds ratio for anemia with a doubling of the 
parasite clearance half-life, 1.53; 95% CI, 1.06 to 
2.21; P = 0.02), but there was no association by 
day 28. Apart from the baseline hematocrit, other 
covariates associated with anemia on day 21 
were age (odds ratio with a doubling of age, 1.53; 
95% CI, 1.12 to 2.11; P = 0.008) and initial parasite 
count (odds ratio with an increase in the count by 
a factor of 10, 2.09; 95% CI, 1.00 to 4.35; P = 0.05). 
The development of anemia was not associated 
with the dose of the artemisinin derivative.
Treatment Efficacy
Patients were followed for 28 days in Kinshasa 
and for 42 days in Pailin, Attapeu, Binh Phuoc, 
Shwe Kyin, and Pingilikani. P. falciparum parasit-
emia recurred after day 14 in 39 patients (6 cases 
of recrudescence). Treatment efficacy corrected 
by means of PCR genotyping was uniformly high 
for all regimens at all sites (Table 3).
Safety
A total of 12 serious adverse events were re-
ported at seven sites: acute alcohol withdrawal 
(in 2 patients), anemia requiring blood transfu-
sion (in 3 patients), bacterial infection (in 3 pa-
tients), and acute asthma, viral respiratory tract 
infection, upper gastrointestinal bleeding, and a 
febrile convulsion (in 1 patient each) (Table S5 in 
the Supplementary Appendix).
Discussion
Artemisinin-resistant P. falciparum is now firmly 
established in eastern Myanmar, western Cam-
bodia and Thailand, and southern Vietnam, and 
it is emerging in southern Laos and northeastern 
Cambodia. Despite the recent spread of resistance, 
we found that artemisinin-based combination ther-
apies in this region were still highly efficacious, 
presumably because of increased reliance on the 
efficacy of the partner drug as the potency of the 
artemisinin component waned. However, rates of 
treatment failure with artesunate–mefloquine in 
Thailand and with dihydroartemisinin–piperaquine 
in Cambodia have increased by a factor of more 
than 5.11,25-29 Mathematical modeling, in vitro 
experiments, and transcriptomic studies all sug-
gest that reduced susceptibility of ring-stage 
parasites causes the slow parasite clearance.5-9 
Strong evidence30,31 of genetic linkage to a region 
of P. falciparum chromosome 13 has now been 
translated10 into the discovery of a molecular 
marker — single-nucleotide polymorphisms (SNPs) 
in the propeller region of a kelch protein encoded 
by kelch13.
In this large study, multiple kelch13 SNPs were 
highly predictive of slow parasite clearance and 
were associated with more than double the para-
site clearance half-life. Some SNPs (notably C580Y) 
predominated. With one exception, only one SNP 
per propeller domain was ever present in “clon-
al” infections. The majority of SNPs were associ-
ated with a similar prolongation of the parasite 
clearance half-life. The geographic distribution 
of these SNPs confirms that artemisinin resis-
tance has emerged and spread extensively in main-
land Southeast Asia. Widespread availability of 
artemisinin monotherapies, poor-quality arte-
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misinin-based combination therapies and mono-
therapies containing subtherapeutic amounts of 
active ingredients, and unregulated use of anti-
malarial agents, plus the unusual genetic struc-
ture of parasites in this region,32 may have con-
tributed to the selection of resistant parasites.
Simple surrogate measures for the parasite 
clearance rate, such as the proportion of patients 
with detectable parasitemia on day 3, have been 
useful in ruling out resistance, but they are im-
precise and depend on the pretreatment parasite 
density, accurate timing of samples, and reliable 
counting.21 Parasite clearance rates or half-lives 
are preferable but they are still influenced by 
many factors, including antimalarial-drug dos-
ing, pharmacokinetics, and pharmacodynamics, 
as well as host immunity.4,5,12,13,18,33 Sequencing 
of kelch13 provides a potential tool for rapid epi-
demiologic assessment.
Patients in Bangladesh, Nigeria, and the 
Democratic Republic of Congo also occasionally 
had parasite clearance half-life values of more than 
5 hours, but these values were not associated with 
kelch13 polymorphisms. Conversely, 3 patients in 
Kinshasa who had kelch13 propeller polymorphisms 
had very rapid parasite clearance. However, non-
synonymous SNPs before kelch13 position 441 
(not associated with slow parasite clearance) 
were also more frequent in Kinshasa (30 of 72 pa-
tients). The ratio of proximal SNPs to distal 
SNPs, relative to the 441 cutoff point, may be 
informative in epidemiologic assessments. Slow 
parasite clearance after treatment with artemis-
inin derivatives was observed infrequently soon 
after they were introduced in Asia.34 Detection of 
persistently dormant yet drug-sensitive parasites 
and splenic hypofunction are possible explana-
tions.35 Another factor is the initial doses of 
artemisinin derivatives, which vary considerably 
among different artemisinin-based combination 
therapies and range from 1.6 mg of artemether 
per kilogram in artemether–lumefantrine to 2.5 
mg of dihydroartemisinin per kilogram in dihy-
droartemisinin–piperaquine to 4 mg of artesunate 
Table 3. Efficacy of Various Treatment Regimens at Sites that Followed Patients for More than 14 Days.*
Study Site Treatment
Duration  
of Treatment
Duration  
of Follow-up
Total No.  
of Patients
No. of Patients 
with Recurrence  
of Infection Efficacy
Without PCR 
Correction
With PCR 
Correction†
days % (95% CI)
Pailin, Cambodia AS4-DP 6 42 100 2 97.7 (90.9–99.4) 97.7 (90.9–99.4)
Vietnam
Binh Phuoc AS2-DP 6 42 60 0 100 (93.2–100) 100 (93.2–100)
Binh Phuoc AS4-DP 6 42 60 0 100 (93.0–100) 100 (93.0–100)
Laos
Attapeu AS4-AL 6 42 60 1 98.2 (88.0–99.8) 100 (93.5–100)
Attapeu‡ AS2-AL 6 42 60 2 96.6 (86.9–99.1) 100 (93.6–100)
Myanmar
Shwe Kyin AS4-AL 6 42 40 0 100 (87.9–100) 100 (87.9–100)
Shwe Kyin AS2-AL 6 42 40 0 100 (89.0–100) 100 (89.0–100)
Pingilikani, Kenya§ AS2 7 42 59 19 65.5 (51.3–76.4) 93.4 (80.8–97.9)
Democratic Republic 
of Congo
Kinshasa AS4-AL 6 28 60 3 94.6 (84.3–98.2) 100 (93.6–100)
Kinshasa AL 3 28 60 12 77.4 (64.3–88.2) 98.3 (88.4–99.8)
* AL denotes artemether–lumefantrine, AS4 artesunate at a dose of 4 mg per kilogram of body weight, AS2 artesunate at a dose of 2 mg per kilo-
gram, and DP dihydroartemisinin–piperaquine.
† For recurrent infections, polymerase-chain-reaction (PCR) genotyping was performed with the use of msp1, msp2, and glurp as genetic markers 
for Plasmodium falciparum to distinguish a recrudescence from a newly acquired infection.16 In Kenya, only msp2 was used for genotyping.17
‡ Genotypes were missing for two patients.
§ DNA failed to amplify in three patients.
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per kilogram in other artemisinin-based com-
bination therapies. In Kinshasa, parasite clear-
ance was faster with artesunate at a dose of 4 mg 
per kilogram per day than with artemether at a 
dose of 1.6 mg per kilogram per day, suggest-
ing a submaximal effect with artemether.
Efficacy was good with the 6-day treatment 
course in areas of established artemisinin resis-
tance. The day 42 failure rate of 2% (95% CI, 1 to 
9) after 3 days of artesunate followed by 3 days of 
dihydroartemisinin–piperaquine in Pailin is more 
than 10 times lower than the recent failure rate 
of 25% (95% CI, 10 to 51) with the standard 
3-day dihydroartemisinin–piperaquine regimen 
in the same area.26 Prolonged courses of treat-
ment are one option for treating artemisinin-
resistant malaria.
The higher proportions of pretreatment and 
post-treatment gametocytemia in patients with 
slow parasite clearance suggest that artemisinin-
resistant P. falciparum infections have a trans-
mission advantage that may drive the spread of 
resistance. This increase in post-treatment ga-
metocytemia may be a harbinger of increased 
treatment failure rates, as reported previously 
with sulfadoxine–pyrimethamine.36 In 2012, the 
WHO reinforced its recommendation to add a 
single gametocyto cidal dose of primaquine to 
artemisinin-based combination therapies in or-
der to limit the spread of artemisinin resis-
tance,37 but the limited adoption of this policy 
has been disappointing.
Resistance to artemisinin has not been con-
tained and has now emerged or spread across 
Southeast Asia. The spread of artemisinin resis-
tance and the consequent emergence of resistance 
to the increasingly unprotected partner drugs in 
artemisinin-based combination regimens may 
well reverse the substantial recent gains in ma-
laria control. New antimalarial drugs are under 
development but will not be available for several 
years. Radical measures will be necessary in 
Southeast Asia to prevent resistance to artemisi-
nins and their partner drugs from spreading to 
the Indian subcontinent and then to Africa.
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